BMY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Bristol-Myers Squibb Company and a Lead Plaintiff Deadline of April 10, 2018

NEW YORK, Feb. 28, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of investors who purchased Bristol-Myers Squibb Company ("Bristol-Myers") (NYSE:BMY) securities between January 27, 2015 and October 9, 2016.

Click here to learn about the case: http://www.wongesq.com/pslra-c/bristol-myers-squibb-company?wire=3. There is no cost or obligation to you.

According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) Bristol-Myers' CheckMate-026 trial was more likely to fail than Defendants were representing; (2) Bristol-Myers' CheckMate-026 trial failed more severely than the Company indicated in its August 5, 2016 announcements and disclosures; and (3) as a result of the foregoing, Defendants' statements about Bristol-Myers' business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. On August 5, 2016, Bristol-Myers revealed that its CheckMate-026 trial exploring the use of Opdivo (nivolumab) as monotherapy failed to meet its primary endpoint of progression-free survival. Following this news, Bristol-Myers stock fell 16% to close at $63.28 per share on August 5, 2016. Then on October 9, 2016, Bristol-Myers revealed the final primary analysis of CheckMate-026, and that the overall Opdivo survival was only 14.4 months compared to chemotherapy's 13.2 months. Following this news, Bristol-Myers stock dropped over 10%, to close at $49.81 per share on October 10, 2016.

If you suffered a loss in Bristol-Myers you have until April 10, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/bristol-myers-squibb-company?wire=3.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]